Citations (13)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Wenping Gong, Yan Liang & Xueqiong Wu. (2018) The current status, challenges, and future developments of new tuberculosis vaccines. Human Vaccines & Immunotherapeutics 14:7, pages 1697-1716.
Read now
Read now
Jalil Hakimi, Ali Azizi, Salvador F. Ausar, Stephen M. Todryk, Nausheen Rahman & Roger H. Brookes. (2017) An adjuvant-modulated vaccine response in human whole blood. Human Vaccines & Immunotherapeutics 13:9, pages 2130-2134.
Read now
Read now
Majid Faridgohar & Hassan Nikoueinejad. (2017) New findings of Toll-like receptors involved in Mycobacterium tuberculosis infection. Pathogens and Global Health 111:5, pages 256-264.
Read now
Read now
Susan M Twine, Kelly M Fulton, John Spika, Marc Ouellette, Jennifer F Raven, J Wayne Conlan, Lakshmi Krishnan, Luis Barreto & James C Richards. (2015) Next Generation Vaccine Biomarkers workshop October 30–31, 2014 – Ottawa, Canada. Human Vaccines & Immunotherapeutics 11:12, pages 2923-2930.
Read now
Read now
Articles from other publishers (9)
Li Zhuang, Zhaoyang Ye, Linsheng Li, Ling Yang & Wenping Gong. (2023) Next-Generation TB Vaccines: Progress, Challenges, and Prospects. Vaccines 11:8, pages 1304.
Crossref
Crossref
Xin Liu, Haoran Li, Shanshan Li, Jinfeng Yuan & Yu Pang. (2023) Maintenance and recall of memory T cell populations against tuberculosis: Implications for vaccine design. Frontiers in Immunology 14.
Crossref
Crossref
Emma Whitlow, Abu Salim Mustafa & Shumaila Nida Muhammad Hanif. 2023. Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges. Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges
211
232
.
Amber Troy, Sandra C. Esparza-Gonzalez, Alicia Bartek, Elizabeth Creissen, Linda Izzo & Angelo A. Izzo. (2020) Pulmonary mucosal immunity mediated through CpG provides adequate protection against pulmonary Mycobacterium tuberculosis infection in the mouse model. A role for type I interferon. Tuberculosis 123, pages 101949.
Crossref
Crossref
Silvia Moreno-Mendieta, Alejandra Barrera-Rosales, Dulce Mata-Espinosa, Jorge Barrios-Payán, Sergio Sánchez, Rogelio Hernández-Pando & Romina Rodríguez-Sanoja. (2019) Raw starch microparticles as BCG adjuvant: Their efficacy depends on the virulence of the infection strains. Vaccine 37:38, pages 5731-5737.
Crossref
Crossref
Acep R. Wijayadikusumah, Weiguang Zeng, Hayley A. McQuilten, Chinn Yi Wong, David C. Jackson & Brendon Y. Chua. (2019) Geometry of a TLR2-Agonist-Based Adjuvant Can Affect the Resulting Antigen-Specific Immune Response. Molecular Pharmaceutics 16:5, pages 2037-2047.
Crossref
Crossref
Sasmit S. Deshmukh, Federico Webster Magcalas, Kristen N. Kalbfleisch, Bruce W. Carpick & Marina D. Kirkitadze. (2018) Tuberculosis vaccine candidate: Characterization of H4-IC31 formulation and H4 antigen conformation. Journal of Pharmaceutical and Biomedical Analysis 157, pages 235-243.
Crossref
Crossref
Liwei He, Jin Su, Marin Ming, Lidice Bernardo, Tricia Chen, Lucy Gisonni-Lex & Beata Gajewska. (2018) Flow cytometry: An efficient method for antigenicity measurement and particle characterization on an adjuvanted vaccine candidate H4-IC31 for tuberculosis. Journal of Immunological Methods 452, pages 39-45.
Crossref
Crossref
Jalil Hakimi, Sepideh Aboutorabian, Frederick To, Salvador F. Ausar, Nausheen Rahman & Roger H. Brookes. 2017. Vaccine Adjuvants. Vaccine Adjuvants
295
304
.